Arcus Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Arcus Biosciences, Inc. (RCUS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $22.05 per share for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-23.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2022-02-23
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2019-09-30 was $5.49, a 39.67% decline year-over-year.
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2019-06-30 was $6.28, a 44.08% decline year-over-year.
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2019-03-31 was $10.36, a 55.56% increase year-over-year.
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2018-09-30 was $9.10, a 454.88% increase year-over-year.
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $22.05, a 90.58% increase from fiscal 2020.
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $11.57, a 82.78% increase from fiscal 2019.
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2019 was $6.33.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2021-12-31 | $22.05 10-K · filed 2022-02-23 | |||
| 2020-12-31 | $11.57 10-K · filed 2022-02-23 | |||
| 2019-12-31 | $6.33 10-K · filed 2022-02-23 | |||
| 2019-09-30 | $5.49 10-Q · filed 2019-11-05 | $6.53 10-Q · filed 2019-11-05 | ||
| 2019-06-30 | $6.28 10-Q · filed 2019-08-06 | $6.63 10-Q · filed 2019-08-06 | ||
| 2019-03-31 | $10.36 10-Q · filed 2019-05-02 | |||
| 2018-09-30 | $9.10 10-Q · filed 2019-11-05 | $7.45 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | $11.23 10-Q · filed 2019-08-06 | $7.29 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $6.66 10-Q · filed 2019-05-02 | |||
| 2017-09-30 | $1.64 10-Q · filed 2018-11-08 | $1.74 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $1.76 10-Q · filed 2018-08-06 | $1.75 10-Q · filed 2018-08-06 | ||
| 2017-03-31 | $1.75 10-Q · filed 2018-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |